Literature DB >> 7453669

The enzyme-linked immunosorbent assay (ELISA) for determination of IgG and IgM antibodies after infection with mumps virus.

M E Nicolai-Scholten, R Ziegelmaier, F Behrens, W Höpken.   

Abstract

Under routine laboratory conditions ELISA was tested for suitability for serological demonstration of specific antibodies of the immunoglobulin classes G and M against mumps virus. Sera from patients with known clinical and virological data were used. The results of ELISA were compared with those of CFT. 45 paired sera were tested in ELISA IgG, 87 first sera in ELISA IgM. Both tests were highly sensitive, antibodies were detected earlier and with higher titers than with the CFT. The ELISA IgM is particularly suitable for early diagnosis of mumps infection with the first serum. In addition 23 paired sera from patients with acute parainfluenza virus infection were examined for cross-reacting antibodies. Low anti-mumps IgG antibody titers were found in some sera. These findings reduced the mumps specificity of the IgG test. In five serum samples from one patient--obtained before, during, and after an infection with mumps--the course of IgG and IgM antibodies could be demonstrated. Advantages and limitations of ELISA IgG and IgM are summarized.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7453669     DOI: 10.1007/bf02121756

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  5 in total

1.  Enzyme immunoassays in diagnostic medicine. Theory and practice.

Authors:  A Voller; D E Bidwell; A Bartlett
Journal:  Bull World Health Organ       Date:  1976       Impact factor: 9.408

2.  Enzyme-linked immunosorbent assay. II. Quantitative assay of protein antigen, immunoglobulin G, by means of enzyme-labelled antigen and antibody-coated tubes.

Authors:  E Engvall; K Jonsson; P Perlmann
Journal:  Biochim Biophys Acta       Date:  1971-12-28

3.  Evaluation of enzyme-linked immunosorbent assay (ELISA) for mumps virus antibodies.

Authors:  P O Leinikki; I Shekarchi; N Tzan; D L Madden; J L Sever
Journal:  Proc Soc Exp Biol Med       Date:  1979-03

4.  Rubella complement-fixing antigens derived from the fluid and cellular phases of infected BHK-21 cells: extraction of cell-associated antigen with alkaline buffers.

Authors:  N J Schmidt; E H Lennette
Journal:  J Immunol       Date:  1966-12       Impact factor: 5.422

5.  A simple method for detecting antibodies to rubella.

Authors:  A Voller; D E Bidwell
Journal:  Br J Exp Pathol       Date:  1975-08
  5 in total
  6 in total

Review 1.  Mumps: an Update on Outbreaks, Vaccine Efficacy, and Genomic Diversity.

Authors:  Eugene Lam; Jennifer B Rosen; Jane R Zucker
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

2.  Detectability of IgM antibodies against TBE virus after natural infection and after vaccination.

Authors:  H Hofmann; C Kunz; F X Heinz; H Dippe
Journal:  Infection       Date:  1983 May-Jun       Impact factor: 3.553

3.  Immunoglobulin class and immunoglobulin G subclass enzyme-linked immunosorbent assays compared with microneutralization assay for serodiagnosis of mumps infection and determination of immunity.

Authors:  G A Linde; M Granström; C Orvell
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

4.  Virus genotypes and responses of serum-specific antibodies in children with primary mumps and mumps reinfection.

Authors:  Rika Sakata; Akira Nagita; Minoru Kidokoro; Atsushi Kato; Keiki Ogino
Journal:  Pediatr Res       Date:  2015-08-12       Impact factor: 3.756

5.  Hemadsorption immunosorbent technique for determination of mumps immunoglobulin M antibody.

Authors:  J T van der Logt; F W Heessen; A M van Loon; J van der Veen
Journal:  J Clin Microbiol       Date:  1982-01       Impact factor: 5.948

6.  Rapid diagnosis of acute mumps infection by a direct immunoglobulin M antibody capture enzyme immunoassay with labeled antigen.

Authors:  J P Gut; C Spiess; S Schmitt; A Kirn
Journal:  J Clin Microbiol       Date:  1985-03       Impact factor: 5.948

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.